Shruti Singh, MD
Hematology & Oncology · Dyer, INNPI 1619210143
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (50.3%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 60 manufacturers reported payments, led by E.r. Squibb & Sons, L.L.C. at 25.6% of the total. Reporting peaked in 2023 at $60,916 and has fallen 70.8% since, to $17,768 in 2025. Among hematology & oncology clinicians in IN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 768 payments — averaging $203.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$40K
- AstraZeneca$34K
- Daiichi Sankyo Inc.$32K
- Amgen$10K
- Pharmacosmos Therapeutics Inc.$6K
- Beigene USA, Inc.$4K
- plus $29K from 54 others
Across 51 payments — averaging $14,267 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$308K
- AstraZeneca$113K
- Merck$102K
- Bristol Myers Squibb$84K
- Karyopharm Therapeutics Inc.$43K
- Biontech SE$43K
- plus $35K from 1 others
What the payments were for
- Consulting fees$78,44050%
- Speaking & faculty fees$48,83731%
- Travel & lodging$9,6976%
- Food & beverage$17,41211%
- Education$9351%
- Other$6650%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$155,986 in reported general payments places this provider in the 90th percentile of 224 hematology & oncology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 28 | $424,587 |
| TavalisseFostamatinib Disodium | 11 | $163,648 |
| CalquenceAcalabrutinib Maleate | 11 | $160,263 |
| XareltoRivaroxaban | 15 | $21,871 |
| VenclextaVenetoclax | 19 | $18,616 |
| EliquisApixaban | 14 | $12,578 |
| Anastrozole | 75 | $1,441 |
| Ondansetron Hcl | 42 | $900 |
| Hydroxyurea | 25 | $567 |
| Dexamethasone | 31 | $475 |
| Acyclovir | 22 | $386 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 13 | $319 |
| LoperamideLoperamide Hcl | 16 | $178 |
| Levofloxacin | 13 | $119 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Incyte CorporationJakafi | $1,097 | $424,58728 claims |
| Rigel Pharmaceuticals, Inc.Tavalisse | $66 | $163,64811 claims |
| AstraZenecaCalquence | $33,664 | $160,26311 claims |
| Johnson & JohnsonXarelto | $2,632 | $21,87115 claims |
| AbbVieVenclexta | $495 | $18,61619 claims |
| PfizerEliquis | $338 | $12,57814 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 224 hematology & oncology providers in Indiana.
Other hematology & oncology in Dyer
- Neel ShahDyer$464K
- Gowri RamadasDyer$31K
- Mohamad KassarDyer$28K
- Richard GaynorIndianapolis$3.7M
- Ruemu BirhirayIndianapolis$3.1M
- Chandler ParkCorydon$661K
- Ahad SadiqFort Wayne$430K
- Ajay KandraMadison$408K
- Anand TandraIndianapolis$280K
- Attaya SuvannasankhaIndianapolis$253K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.